Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
•
Hepatology
When treating fatty liver disease with resmetirom, how often should a FibroScan be repeated to assess treatment response?
Related Questions
Is the Enhanced Liver Fibrosis (ELF) test superior to the FIB-4 test in the diagnosis of MASLD?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
How many days prior to elective major surgery do you recommend holding oral GLP 1 R agonist therapy?
Why is it recommended to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after tirzepatide initiation but not with semaglutide?
In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?
Should orlistat be avoided in patients with a history of kidney stones?
Can procalcitonin be used as a marker for endothelial dysfunction emanating from chronic inflammation of obesity?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
